Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Operating Leases (2022 - 2025)

Historic Operating Leases for Altimmune (ALT) over the last 4 years, with Q3 2025 value amounting to $1.2 million.

  • Altimmune's Operating Leases fell 1691.78% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 million, marking a year-over-year decrease of 1691.78%. This contributed to the annual value of $1.4 million for FY2024, which is 70114.29% up from last year.
  • According to the latest figures from Q3 2025, Altimmune's Operating Leases is $1.2 million, which was down 1691.78% from $1.3 million recorded in Q2 2025.
  • Altimmune's Operating Leases' 5-year high stood at $1.5 million during Q2 2024, with a 5-year trough of $44000.0 in Q1 2024.
  • Its 4-year average for Operating Leases is $1.0 million, with a median of $1.3 million in 2025.
  • Its Operating Leases has fluctuated over the past 5 years, first plummeted by 7395.83% in 2023, then skyrocketed by 295000.0% in 2025.
  • Altimmune's Operating Leases (Quarter) stood at $672000.0 in 2022, then plummeted by 73.96% to $175000.0 in 2023, then surged by 701.14% to $1.4 million in 2024, then dropped by 13.48% to $1.2 million in 2025.
  • Its Operating Leases was $1.2 million in Q3 2025, compared to $1.3 million in Q2 2025 and $1.3 million in Q1 2025.